In this issue:
Higher lung cancer risk with ACEIs
Sequencing outcomes in lung brain metastases
Afatinib + bevacizumab after acquired resistance to EGFR TKIs in NSCLC
Gene-environment interaction increases risk of pleural mesothelioma
Validation of adjuvant chemotherapy response prediction in lung cancer
Alectinib vs crizotinib in ALK + NSCLC
Third-line nivolumab monotherapy in recurrent SCLC
Preoperative staging with EBUS in cN0/n1 lung cancer
Time delays in lung cancer referral in a North Queensland study
Adjuvant erlotinib benefits EGFR-mutant NSCLC
Please login below to download this issue (PDF)